Janssen Ramps Up Ritalin and Opioid Production
Published Date: 2/18/2025
Notice
Summary
Janssen Pharmaceuticals wants to officially make big batches of three strong medicines: Methylphenidate, Hydromorphone, and Tapentadol. This move affects drug makers and users by ensuring these drugs are made safely and legally. People can share their thoughts or ask for a hearing by April 21, 2025, so don’t miss the deadline!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Janssen Seeks Bulk Manufacturer Registration
Janssen Pharmaceuticals applied on December 4, 2024 to be registered as a bulk manufacturer of three Schedule II controlled substances: Methylphenidate (code 1724), Hydromorphone (code 9150), and Tapentadol (code 9780). The company plans to bulk manufacture these substances as internal-use intermediates for sale to its customers, and the application is open for comments or hearing requests through April 21, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-02739, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to make big batches of two powerful drugs, Ibogaine and MDMA, for research only. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 21, 2025. This move could boost scientific studies but doesn’t change drug sales or use rules.
Next: 2025-02777, Combined Notice of Filings
The Federal Energy Regulatory Commission got new filings about natural gas pipeline rates and refunds from several companies. These filings include updates to negotiated rates and compliance changes, with some taking effect as soon as February 11, 2025. If you want to speak up or get involved, you need to comment by late February, and these changes could affect pipeline costs and contracts.